2015 Compound Libraries
|
|
- Sibyl Crawford
- 8 years ago
- Views:
Transcription
1 21 Compound Libraries
2 Compound Libraries (96-Well) Contents What is a Compound Library? Compound Libraries are ready-to-use chemical libraries used for drug discovery, lab drug screening, drug target identification, and other pharmaceutical-related applications. The libraries consist of a unique and diverse collection of over 2,1 small molecules with validated biological and pharmacological activities. L17 Bioactive Compound Library...1 L12 Kinase Inhibitor Library...2 L13 FDA-approved Drug Library...3 L11 Inhibitor Library... 4 L19 Epigenetics Compound Library... Safety and effectiveness of the compounds has been demonstrated by preclinical and clinical research, and many of the compounds are FDA-approved. L14 Natural Product Library... L3 Target Selective Inhibitor Library...6 The collections of unique small molecules, which include inhibitors, activators, antagonists, and agonists, are focused on over 2 targets that are part of more than 2 signaling pathways. These pathways include, among many others, apoptosis, /Akt/, and MAPK pathways. L22 GPCR Compound Library...7 L3 Anti-cancer Compound Library...8 L18 Tyrosine Kinase Inhibitor Library...9 L21 Stem Cell Signaling Compound Library...9 L23 Cambridge Cancer Compound Library...1 L24 Pfizer Licensed Compound Library...11 L26 Compound Library L27 Ion Channel Ligand Library...12 Compound Library Advantages Structurally diverse, medicinally active, and cell permeable Rich documentation with structure, IC, and customer reviews NMR and HPLC validated to ensure high purity 4 4 You can customize your library by selecting compounds of interest. Build the right library for your research endeavors by choosing from compounds in all of our available libraries. 4 You could select: 4 L28 /Akt Inhibitor Library...13 L33 Apoptosis Compound Library...13 L34 MAPK Inhibitor Library...14 L2 Protease Inhibitor Library...14 L31 Anti-infection Compound Library...1 L29 Anti-diabetic Compound Library Specific Compounds Quantities Plate map Concentration Please contact us at info@selleckchem.com to customize your library. 1 1 Product Citations Nat Med, 214, 2(8): 94-6 Nat Cell Biol, 21, 17(1): 7-67 Nat Prod Rep, 214, 31(6): Cancer Res, 214, 74: 172 Oncogene, 214, 1.138/onc Oncotarget, 214, (1): Mol Cancer Ther, 214, 13(2): ACS Chem Biol, 214, 9(): Mol Cancer Res, 214, 12(): Antimicrob Agents Chemother, 214, 8(8): Format (Dry/solid or DMSO solution) 1
3 Bioactive Compound Library Cat.No. Kinase Inhibitor Library L17 Bioactive Compound Library Cat.No. A unique collection of 378 kinase inhibitors for high throughput screening (HTS) and Bioactivity and safety confirmed by preclinical research and clinical trials Some inhibitors have been approved by the FDA Most are ATP competitive Rich documentation with structure, IC, and customer reviews A unique collection of 192 bioactive chemical compounds for high throughput screening (HTS) and Bioactivity and safety confirmed by preclinical research and clinical trials Some compounds have been approved by the FDA Includes most Selleck inhibitors, APIs, natural products, and chemotherapeutic agents Rich documentation with structure, IC, and customer reviews 1 μl/well (1 mm solution) L12 Kinase Inhibitor Library 2 μl/well (1 mm solution) 1 μl/well (1 mm solution) 2 μl/well (1 mm solution) 3 Number of Kinase Inhibitors Re cep tor 2 es t og en 2 rog en /pr og Est Number of Bioactive Compounds 1 3 rs he Ot AM PA /ka ina te Re c ep tor 1 Phone: (832) info@selleckchem.com 2
4 FDA-approved Drug Library Inhibitor Library Cat.No. L13 FDA-approved Drug Library Cat.No. L11 Inhibitor Library A unique collection of 118 FDA approved drugs for high throughput screening (HTS) and Locate new targets for old drugs Bioactivity and safety confirmed by clinical trials All compounds have been approved by FDA Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc Number of FDA-approved Compounds AMPA/kainate Receptor A unique collection of 1224 small molecule inhibitors for high throughput screening (HTS) and Bioactivity and safety confirmed by preclinical research and clinical trials Some inhibitors have been approved by the FDA Includes most Selleck inhibitors, APIs, natural products, and chemotherapeutic agents AChR V RAAS MEK Raf GluR Akt p38 MAPK ATPase Bcl-2 IGF-1R ATM/ATR DPP-4 DUB HER2 IκB/IKK p3 PLK PPAR Rho CFTR Kinesin Syk Aromatase Caspase Chk GPR Integrase MMP NF-κB PKC STAT ALK BTK CETP Factor Xa IAP MAO Mdm2 PDK-1 TNF-alpha c-kit CRM1 DHFR FAAH JNK LRRK2 p97 camp CaSR Dynamin FXR IDO PAK PERK P-gp S6 Kinase TRPV APC BACE c-myc CSF-1R CXCR DNA-PK ERK gp12/cd4 Integrin NOD1 PAFR PKA Survivin Tie-2 VDA Wee1 -HT Receptor HSP (e.g. HSP9) Sodium Channel Calcium Channel P4 (e.g. CYP17) Androgen Receptor Wnt/beta-catenin Potassium Channel Dehydrogenase Opioid Receptor Cysteine Protease HIV Protease Transferase Carbonic Anhydrase GABA Receptor HCV Protease P2 Receptor Serine Protease Hydroxylase OX Receptor Proton Pump S1P Receptor Telomerase -alpha Reductase Ferroptosis Liver X Receptor LPA Receptor Adenosine Receptor Beta Amyloid E1 Activating E2 Conjugating E3 Ligase Ephrin receptor MT Receptor IL Receptor Phosphorylase Substance P Adrenergic Receptor Histamine Receptor Dopamine Receptor Reverse Transcriptase Histone Methyltransferase Microtubule Associated Cannabinoid Receptor DNA Methyltransferase HMG-CoA Reductase Histone Demethylase AMPA/kainate Receptor Phospholipase (e.g. PLA) Histone Acetyltransferase Procollagen C Proteinase Vasopressin Receptor 3 Phone: (832)
5 Epigenetics Compound Library / Natural Product Library Target Selective Inhibitor Library Cat.No. L19 Epigenetics Compound Library Cat.No. L3 Target Selective Inhibitor Library A unique collection of 128 small molecule modulators (inhibitors and activators) with biological activity used for epigenetics research and associated assays. A variety of structurally and mechanistically different compounds are included A valuable tool for chemical genomics, epigenetic target identification in pharmacogenomics, and other biological applications NMR and HPLC validated to ensure the highest purity MAO Histone Methyltransferase DNA Methyltransferase Histone Demethylase Histone Acetyltransferase Sodium Channel A unique collection of 464 validated bioactive compounds covering over 14 targets Each compound was selected based on its ability to principally interact with a single target, leading to minimal off-target activity Selectivity is at least 1-fold higher relative to non-primary target(s) Targets cover a wide variety of signaling pathways, including /Akt, MAPK, PTK,, apoptosis, and others This unique tool is ideal for studying mechanisms of action or for target screening Compounds are structurally diverse, biologically active, and cell permeable Selleck provides rich supporting documentation which includes compound structure, IC, and customer reviews Compounds are NMR and HPLC validated to ensure our customers receive high purity compounds ATM/ATR GluR Integrase LRRK2 JNK LPA Receptor PAK PKA DNA Methyltransferase RAAS Rho STAT NF-κB OX Receptor P2 Receptor Substance P Survivin GABA Receptor AChR V p3 PDK-1 Tie-2 HMG-CoA Reductase ALK p97 PERK VDA Opioid Receptor GPR P-gp Wee1 P4 (e.g. CYP17) Aromatase PKC Adrenergic Receptor Potassium Channel Cat.No. L14 Natural Product Library MEK PLK Caspase CETP CFTR PPAR Raf S1P Receptor S6 Kinase Transferase Histamine Receptor -HT Receptor Sodium Channel -alpha Reductase A unique collection of 131 natural products for high throughput screening (HTS) and Structurally diverse, bioactive, and cell permeable Rich documentation with structure and IC NMR and HPLC validated ensure high purity Akt ATPase Bcl-2 BTK Chk CRM1 DHFR DPP-4 FAAH Syk Telomerase TNF-alpha TRPV Beta Amyloid CSF-1R CXCR E1 Activating Cysteine Protease Dopamine Receptor HSP (e.g. HSP9) Cannabinoid Receptor Adenosine Receptor AMPA/kainate Receptor Histone Demethylase Liver X Receptor Microtubule Associated Reverse Transcriptase DUB Factor Xa camp CaSR E2 conjugating E3 Ligase Dehydrogenase Histone Acetyltransferase IκB/IKK Kinesin Dynamin Ferroptosis ERK gp12/cd4 Histone Methyltransferase Phospholipase (e.g. PLA) Phosphorylase MAO IDO Wnt/beta-catenin Serine Protease MMP IAP FXR MT Receptor Androgen Receptor Vasopressin Receptor p38 MAPK IGF-1R HER2 NOD1 Calcium Channel Integrase Hydroxylase PAFR Carbonic Anhydrase Phone: (832)
6 GPCR Compound Library Anti-cancer Compound Library Cat.No. L22 GPCR Compound Library Cat.No. L3 Anti-cancer Compound Library A unique collection of 24 small molecules targeting G protein coupled receptors used in GPCR screening by pharmaceutical and biotechnology companies in various research and drug development projects All of the small molecules in the GPCR library are well characterized with biological and pharmaceutical activity A powerful tool for discovering GPCR-based drugs that are the richest signal receptor targets for drug discovery. It is estimated about 2 so-called orphan GPCRs are functionally unknown, as a result, use of our GPCR Small Molecule Compound Library for screening the functionally unknown GPCRs may yield potentially new GPCR-based drug candidates NMR and HPLC validated to ensure the highest purity AChR GluR camp CaSR CXCR -HT Receptor GABA Receptor P2 Receptor OX Receptor S1P Receptor MT Receptor Opioid Receptor Adrenergic Receptor Histamine Receptor Dopamine Receptor Cannabinoid Receptor AMPA/kainate Receptor A unique collection of 386 anti-cancer small molecules for 12 types of cancers: Breast Cancer, Leukemia, Lung Cancer, Lymphoma, etc This library contains inhibitors of,,,,,, etc Some compounds have been approved by the FDA V MEK PLK Aromatase Bcl-2 Kinesin Raf Mdm2 p38 MAPK Akt c-kit IGF-1R PKC STAT TNF-alpha ATM/ATR Caspase Chk FXR HER2 IL Receptor IκB/IKK JNK PDK-1 Rho Telomerase APC BTK CETP DHFR DNA-PK DUB ERK FAAH Hydroxylase IAP IDO MMP p3 PAK PERK PPAR Substance P Survivin Syk Tie-2 Transferase VDA Wee1 Microtubule Associated HSP (e.g. HSP9) Androgen Receptor Wnt/beta-catenin DNA Methyltransferase S1P Receptor Dehydrogenase Histone Demethylase HMG-CoA Reductase Liver X Receptor 7 Phone: (832)
7 Tyrosine Kinase Inhibitor Library / Stem Cell Signaling Compound Library Cambridge Cancer Compound Library Cat.No. L18 Tyrosine Kinase Inhibitor Library Cat.No. L23 Cambridge Cancer Compound Library A unique collection of 141 tyrosine kinase inhibitors for high throughput screening (HTS) and Bioactivity and safety confirmed by preclinical research and clinical trials Some tyrosine kinase inhibitors have been approved by FDA Structurally diverse, medicinally active and cell permeable Rich documentation with structure, IC and customer reviews NMR and HPLC to ensure the high purity V IGF-1R HER2 Syk ALK BTK c-kit Cat.No. L21 CSF-1R Tie-2 VDA Ephrin receptor Stem Cell Signaling Compound Library A unique collection of 81 small molecule inhibitors with biological activity used for stem cell regulatory and signaling pathway research. All of the small molecule inhibitors in the stem cell screening library are well characterized with biological and pharmaceutical activity A powerful tool for researching the mechanism behind stem cells, regenerative therapy, means differentiation, drug screening based on tumor stem cells, as well as other pharmaceutical and biological applications The stem cell inhibitor library contains small molecules associated with signaling pathways which modulate the function of stem cells such as Wnt, Notch, SMAD, and Hedgehog signaling NMR and HPLC validated to ensure the highest purity A highly value-added library derived through a collaboration with researchers at the MIT Koch Institute A unique collection of 313 cancer-targeted compounds for high throughput screening (HTS) and Embraces the whole spectrum of cancer targets, from kinases to Notch signaling, to metabolic targets Structurally diverse, medicinally active and cell permeable Rich documentation with structure and IC NMR and HPLC to ensure the high purity V Raf Bcl-2 MEK Kinesin PLK Akt ATM/ATR Chk c-kit FXR IGF-1R IκB/IKK PKC APC BTK Caspase CETP DHFR DNA-PK FAAH Mdm2 NF-κB p3 PDK-1 PPAR Rho STAT Survivin Syk Tie-2 VDA Wee1 Aromatase p38 MAPK S1P Receptor Telomerase TNF-alpha IL Receptor S6 Kinase Substance P Transferase Microtubule Associated Androgen Receptor DNA Methyltransferase HSP (e.g. HSP9) Dehydrogenase Histone Methyltransferase HMG-CoA Reductase Liver X Receptor Wnt/beta-catenin Wnt/beta-catenin PKC BACE STAT 9 Phone: (832)
8 Pfizer Licensed Compound Library Compound Library / Ion Channel Ligand Library Cat.No. L24 Pfizer Licensed Compound Library Cat.No. L26 Compound Library All 8 compounds are licensed by Pfizer and have been marketed or clinically proven bioactive Wide range of potential uses: from anti-cancer compounds (Bosutinib) to a glycylcycline antiobiotic (Tigecycline) to combat the growing prevalence of antibiotic resistance Purchase as a diverse library or individually to meet your drug-discovery needs Reliability Guarantee: All compounds are developed, validated, and manufactured by Pfizer All compounds are validated using NMR and HPLC Detailed preclinical research data and safety information available A unique collection of 12 small molecules with autophagy-inducing or autophagy-inhibiting activity A useful tool for studying the roles of molecules in autophagy Targets,,,,, E3 Ligase, Calcium Channel,, etc V HER2 -HT Receptor Calcium Channel Phosphorylase IκB/IKK Calcium Channel Opioid Receptor Adrenergic Receptor Potassium Channel LRRK2 APC Microtubule Associated Potassium Channel MEK Aromatase Dopamine Receptor Procollagen C Proteinase Bcl-2 ATPase Mdm2 Adrenergic Receptor Serine Protease CETP camp Sodium Channel RAAS Factor Xa P4 (e.g. CYP17) DUB Proton Pump Dopamine Receptor AChR FAAH p38 MAPK Proton Pump Histamine Receptor E1 Activating Survivin S6 Kinase Sodium Channel HMG-CoA Reductase p3 p97 E3 Ligase TNF-alpha HSP (e.g. HSP9) IL Receptor HSP (e.g. HSP9) Cat.No. L27 Ion Channel Ligand Library A unique collection of 2 small molecule modulators used for Ion channel research Sodium Channel Calcium Channel Potassium Channel GABA Receptor Dopamine Receptor 11 Phone: (832)
9 /Akt Inhibitor Library / Apoptosis Compound Library MAPK Inhibitor Library / Protease Inhibitor Library Cat.No. L28 /Akt Inhibitor Library Cat.No. L34 MAPK Inhibitor Library A unique collection of 98 small molecule inhibitors used for /Akt/ pathway research A valuable tool for researching the survival, proliferation, and apoptosis of cells Akt ATM/ATR PDK-1 S6 Kinase DNA-PK PKA Other A unique collection of 44 small molecule inhibitors used for MAPK signaling research MEK Raf p38 MAPK JNK ERK Cat.No. L33 Apoptosis Compound Library A unique collection of 3 small molecules used for apoptosis research Bcl-2 p3 Caspase IAP Mdm2 TNF-alpha PERK Survivin Cat.No. L2 Protease Inhibitor Library A unique collection of 43 small molecule inhibitors used for chemical genomics, high-throughput screening (HTS), and Bioactivity and safety confirmed by preclinical research and clinical trials DPP-4 HIV Protease HCV Protease Serine Protease Caspase Cysteine Protease MMP BACE 13 Phone: (832)
10 Anti-infection Compound Library / Anti-diabetic Compound Library Cat.No. L31 Anti-infection Compound Library A unique collection of 118 anti-infective small molecules with biological activity of antibiotics, antifungal drugs,anti-hiv,etc The compounds in this library mainly include sulfonamides, aminoglycosides, tetracyclines and macrolides A useful tool to research infectious disease for academic institutions, medical research organizations, and the pharmaceutical industry Integrase Reverse Transcriptase Cysteine Protease DHFR HIV Protease P4 (e.g. CYP17) NF-κB HCV Protease Serine Protease Cat.No. L29 Anti-diabetic Compound Library A unique collection of 32 small molecules affecting the development of diabetes DPP-4 GPR Calcium Channel Transferase PPAR Potassium Channel Dehydrogenase P4 (e.g. CYP17) 1
11 Order & Inquiry Toll Free: Tel: Fax: Delivery Tel: Order & Inquiry Tel: (Language: English, French, Spanish, German) Fax: Delivery Technical Support Tel: x3 (We strive to reply to all inquiries within one business day.) --- Inhibitor Expert (Inhibitors, Compound Libraries)
Molecular Cell Biology. Prof. D. Karunagaran. Department of Biotechnology. Indian Institute of Technology Madras. Module 7 Cell Signaling Mechanisms
Molecular Cell Biology Prof. D. Karunagaran Department of Biotechnology Indian Institute of Technology Madras Module 7 Cell Signaling Mechanisms Lecture 2 GPCR Signaling Receptors - G protein coupled receptors
More informationCall 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationThe Open PHACTS Discovery Platform Semantic data integration for Medicinal Chemists
Pharmacoinformatics Research Group Department of Pharmaceutical Chemistry The Open PHACTS Discovery Platform Semantic data integration for Medicinal Chemists Gerhard F. Ecker Dept. of Pharmaceutical Chemistry,
More informationWe use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
More informationValidated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies
Validated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies Abhishek Saharia, Ph. D. Senior Product Manager Validation Assays Drug Discovery Evolution
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationWeill Graduate School of Medical Sciences of Cornell University Program in Pharmacology. Graduate School Curriculum
Weill Graduate School of Medical Sciences of Cornell University Program in Pharmacology Graduate School Curriculum Weill Graduate School of Medical Sciences Partnership between Weill Medical College and
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationMaster BioMedical Sciences (BMS) Track Cell Biology and Advanced Microscopy
Master BioMedical Sciences (BMS) Track Cell Biology and Advanced Microscopy The five tracks offered in the Medical Biology cluster are: Biochemistry and Metabolic Diseases Cell Biology and Advanced Microscopy
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationM. Ugolini 1,2, G. Babini 1,2, G. Baiocco 1,2, D. Cappelletti 1,2, L. Mariotti 1,2, J. Morini 1,2,3 and A. Ottolenghi 1,2
M. Ugolini 1,2, G. Babini 1,2, G. Baiocco 1,2, D. Cappelletti 1,2, L. Mariotti 1,2, J. Morini 1,2,3 and A. Ottolenghi 1,2 1 Department of Physics, University of Pavia, Pavia, Italy 2 Istituto Nazionale
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationMeccanismi di resistenza all inibizione della via di segnale PI3K/Akt/mTOR nella LAM
Meccanismi di resistenza all inibizione della via di segnale PI3K/Akt/mTOR nella LAM University of Modena and Reggio Emilia Cell Signaling Unit, ChiMOMo Sandra Marmiroli Jessika Bertacchini Laura Mediani
More informationHow To Understand Protein-Protein Interaction And Inhibitors
Protein-Protein Interactions and Inhibitors Alan Naylor Independent Consultant Optibrium Consultants Meeting Cambridge 27 th November 2012 Why PPI inhibitors? PPIs are involved in many biological / disease
More informationDepartment of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
More informationHead of College Scholars List Scheme. Summer Studentship. Report Form
Head of College Scholars List Scheme Summer Studentship Report Form This report should be completed by the student with his/her project supervisor. It should summarise the work undertaken during the project
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationPublikationsliste Claudia Götz
Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography
More informationHigh throughput screening, high content screening, primary and stem cells. new techniques now converging
High throughput screening:layout 1 26/3/09 13:32 Page 25 High throughput screening, high content screening, primary and stem cells new techniques now converging Over the past decade, the use of cell-based
More informationHigh-Throughput Screening at The University of Chicago Cellular Screening Center. Sam Bettis Technical Director sbettis@bsd.uchicago.
igh-throughput Screening at The University of Chicago Cellular Screening Center Sam Bettis Technical Director sbettis@bsd.uchicago.edu igh-throughput Screening at The University of Chicago! Cellular Screening
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationLead generation and lead optimisation:
Lead generation and lead optimisation: the value of linking HT co-structure analysis and HT chemistry The coupling of High Throughput co-structure analysis with focused library generation is not only proving
More informationHow To Understand The Effects Of A Drug On Your Health
Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università
More informationTHE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA
THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA Mitchell Keegan, Ph.D. Vice President of Development, Verastem, Inc. 1
More informationZebrafish Chemical Screens
Zebrafish Chemical Screens 1 Historical look at zebrafish chemical screens 2 The effects of AAF on embryonic development in relation to its carcinogenic role 3 First generation Screens HISAOKA, K. K. (1958).
More informationUSP Medicare Model Guidelines v6.0 (Categories and Classes)
USP Medicare Model Guidelines v6.0 (Categories and Classes) USP Category Analgesics Nonsteroidal Anti-inflammatory Drugs Opioid Analgesics, Long-acting Opioid Analgesics, Short-acting Anesthetics Local
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationPublic-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
More informationSTRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS
STRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS Stephen K. Burley Structural GenomiX, Inc. 10505 Roselle Street, San Diego, CA 92121 sburley@stromix.com www.stromix.com Summary Structural
More informationFragment-based lead generation of reversible inhibitors for lysine-specific demethylases
Fragment-based lead generation of reversible inhibitors for lysine-specific demethylases www.beactica.com Ulf Bremberg CSO Beactica AB Drug Discovery 2015 Elrig 3 Sept 2015 Presentation overview Beactica
More informationFor personal use only
The Company Announcements Platform ASX Limited By E-lodgement PTX Shareholder Newsletter 9 November 2015, Melbourne, Australia: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company,
More informationCancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi
Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.
More informationcansar: integrated cancer knowledgebase
in partnership with cansar: integrated cancer knowledgebase Bissan Al-Lazikani Cancer Research UK Cancer Therapeutics Unit 10 th Dec 2013 Sharing knowledge for drug discovery Resource to effectively integrate
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationTargeted Therapy in an Era of Genomic Medicine. George W. Sledge MD Stanford University
Targeted Therapy in an Era of Genomic Medicine George W. Sledge MD Stanford University Why Do Women Die of Breast Cancer? Bad biology Avoidable deaths Important subsets of breast cancers defined by molecular
More informationUpdate on Clinical Trials and Foundation Funded Grants
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationSupport Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:
More informationParis-Sud / CSC program 2014 PhD project proposal form. Discipline Chemistry
Paris-Sud / CSC program 2014 PhD project proposal form Please convert this file to PDF format before uploading it to http://www.u-psud.fr/csc/ Discipline Chemistry Doctoral School 425 - Therapeutic Innovations:
More informationSuccesses and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationB Cell Generation, Activation & Differentiation. B cell maturation
B Cell Generation, Activation & Differentiation Naïve B cells- have not encountered Ag. Have IgM and IgD on cell surface : have same binding VDJ regions but different constant region leaves bone marrow
More informationLung Cancer Research: From Prevention to Cure!
Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationNew Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto
New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic
More informationPerioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time
Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director
More informationUC Davis Institute for Regenerative Cures A facility supported by the California Institute for Regenerative Medicine
UC Davis Institute for Regenerative Cures A facility supported by the California Institute for Regenerative Medicine Naming Opportunities Opportunity No. Description/Features Gift Amount Institute for
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationUNDERGRADUATE INTERNSHIP OPPORTUNITIES
Understanding the molecular mechanisms of macromolecular machines Biochemistry, Structural Biology, Biophysics Biochemistry & Molecular Pharmacology Brian Kelch brian.kelch@umassmed.edu Project expires:
More informationWadsworth Center. New York State Department of Health. The New Faces BMS
New York State Department of Health The New Faces of BMS The New Faces of BMS Jason Wong Adriana DePesters Jason is enrolled in the PhD course for the Fall session in the Department of Biomedical Science.
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationBuilding innovative drug discovery alliances. Evotec Munich. Quantitative Proteomics to Support the Discovery & Development of Targeted Drugs
Building innovative drug discovery alliances Evotec Munich Quantitative Proteomics to Support the Discovery & Development of Targeted Drugs Evotec AG, Evotec Munich, June 2013 About Evotec Munich A leader
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationINSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance
A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationImmunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany
Services & Products Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany Phone Europe: +49-40-41 33 83-0 Fax Europe: +49-40-41 33 83-14 Phone USA: +1-301-588-4650 info@indivumed.com www.indivumed.com
More informationThe EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationBIOM 255 - Firestein, Winter 2009. Rheumatoid arthritis. Page 1
Rheumatoid arthritis Page 1 Vascular events in RA Synovium in rheumatoid arthritis Non-extra articular RA Extra articular RA Turesson, et al. Ann Rheum Dis. 2007;66:60 Normal Rheumatoid Arthritis Major
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationEvaluation of the role of gene polymorphisms in anticancer drug efficacy using in vitro models
Group members and Contact details Jacques Robert graduated in medicine from the University of Strasbourg in 1974 and received hi Research projects: The objectives of our group are: (1) to identify preclinical
More informationBig Data in Drug Discovery
Big Data in Drug Discovery David J. Wild Assistant Professor & Director, Cheminformatics Program Indiana University School of Informatics and Computing djwild@indiana.edu - http://djwild.info Epochs in
More informationSupporting Information. Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007
Supporting Information Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007 Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007 Supporting Information for A Multiplexed Protein
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationAre polyphenols the life extending structures in humic substances?
Are polyphenols the life extending structures in humic substances? From: J. Berger & R. Sommer, Max-Planck-Institut für Entwicklungsbiologie, Tübingen Nadine Saul 1, Kerstin Pietsch 1, Ralph Menzel 1,
More informationThe New Kid on the Block for Advanced Renal Cell Carcinoma
The New Kid on the Block for Advanced Renal Cell Carcinoma Wyeth Pharmaceuticals recently launched Torisel (temsirolimus), a targeted, first-in-class mtor inhibitor. This new treatment for metastatic renal
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationApplication Note No. 2 / July 2012. Quantitative Assessment of Cell Quality, Viability and Proliferation. System
Application Note No. 2 / July 2012 Quantitative Assessment of Cell Quality, Viability and Proliferation System Quantitative Assessment of Cell Quality, Viability and Proliferation Introduction In vitro
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationFlorida Translational Research Program (FTRP)
Florida Translational Research Program (FTRP) Solicitation of Concept / Assay Development (CAD) Projects for use in Pre-Therapeutic Discovery via High-Throughput Screening (HTS) Purpose of the Program
More informationVersion 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen
Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical
More informationICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
More informationMonoclonal antibody (mab) products are currently a fast
Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,
More informationMOLECULAR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
MOLECULAR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS R. M. Weinshilboum, M.D., Program Director L. Wang, M.D., Ph.D., Program Co-Director D. C. Mays, Ph.D., Associate Program Director Ph.D. Degree Course
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationMédecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
More informationHow To Understand Enzyme Kinetics
Chapter 12 - Reaction Kinetics In the last chapter we looked at enzyme mechanisms. In this chapter we ll see how enzyme kinetics, i.e., the study of enzyme reaction rates, can be useful in learning more
More informationRoopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs
Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs BIO Ventures for Global Health Sharing Innovation in the Fight Against Neglected Tropical Diseases World Intellectual Property
More informationLecture 4 Enzymes Catalytic proteins. Enzymes. Enzymes 10/21/10. What enzymes do therefore is:
Lecture 4 Catalytic proteins Are a type of protein that acts as a catalyst-speeding up chemical reactions A catalyst is defined as a chemical agent that changes the rate of a reaction without being consumed
More informationAAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule
AAGPs TM Anti-Aging Glyco Peptides Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule 1 Acknowledgements This presentation was prepared by Dr. Samer Hussein
More informationFight or Flight Response: Play-by-Play
One of the most remarkable examples of cell communication is the fight or flight response. When a threat occurs, cells communicate rapidly to elicit physiological responses that help the body handle extraordinary
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationGenomic Analysis of Mature B-cell Malignancies
Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:
More informationChapter 20: Antimicrobial Drugs
Chapter 20: Antimicrobial Drugs 1. Overview of Antimicrobial Drugs 2. Antibacterial Drugs 3. Antiviral Drugs 4. Drugs for Eukaryotic Pathogens 1. Overview of Antimicrobial Drugs Antibiotics An antibiotic
More informationCrossing the drug development divide
6 Crossing the drug development divide 35 Crossing the drug development divide Few basic scientists have the expertise to make a drug-like compound, test it in animals and begin the initial steps toward
More informationMicromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -
A Microbiology Services Company Lab Services Research - Consulting - Regulatory Company description is a microbiology services company specializing in antiinfective discovery and development for the pharmaceutical,
More informationAdaptive capabilities of the PI3K/Akt/mTOR axis in Acute Myeloid Leukemia revealed by pathway selective inhibition and phosphoproteome analysis
Adaptive capabilities of the PI3K/Akt/mTOR axis in Acute Myeloid Leukemia revealed by pathway selective inhibition and phosphoproteome analysis University of Padova University of Modena and Reggio Emilia
More informationIntegrating Medicinal Chemistry and Computational Chemistry: The Molecular Forecaster Approach
Integrating Medicinal Chemistry and Computational Chemistry: The Molecular Forecaster Approach Molecular Forecaster Inc. www.molecularforecaster.com Company Profile Founded in 2010 by Dr. Eric Therrien
More informationCombining Immunotherapy and Targeted Therapy in Melanoma
Combining Immunotherapy and Targeted Therapy in Melanoma 8:45 am - 9:15 am Antoni Ribas, M.D., h.d. rofessor of Medicine rofessor of Surgery rofessor of Molecular and Medical harmacology Director, Tumor
More informationCNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 Organisers S. Gail Eckhardt, University of Colorado Denver, Aurora, USA Roy S. Herbst, The University of Texas MD Anderson
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More information